A phase I study of paclitaxel (taxol®) (T) in combination with SDZ PSC 833, a potent modulator of multidrug resistance (MDR)
- 1 September 1994
- journal article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: